MedPath

South Korean Study to Prevent Frailty and Aging-related Diseases Through Lifestyle Intervention

Not Applicable
Recruiting
Conditions
Frailty
Registration Number
NCT06891573
Lead Sponsor
Seong Hye Choi, MD
Brief Summary

The goal of this feasibility randomized controlled trial is to investigate the applicability of software that aims to improve symptoms of frailty by implementing customized interventions such as physical exercise and cognitive training implemented through a mobile app for 16 weeks for patients diagnosed with frailty or prefrailty. The primary outcomes are adherence, retention rates, and recruitment rates. Participants will participate in customized interventions including physical exercise, cognitive training, nutritional guidance, and management of disease related to frailty for 16 weeks.

Detailed Description

The physical exercise program will comprise aerobic exercise, balance-improving exercises, flexibility-enhancing activities, and strength-building exercises targeting major muscle groups through a mobile app . Customized cognitive training, performed using a mobile app, targets the cognitive domains of prospective memory and executive function. Nutritional intervention will be performed to treat frailty symptoms and disease related to frailty through a mobile app. Education and management of disease related to frailty will be done through a mobile app.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
40
Inclusion Criteria
  • 60-90 years of age
  • Residing in the community
  • Total score of Modified Fried frailty phenotype score ≥ 1 point
  • Korean Mini-Mental State Examination-2 z-score ≥ -1.5
  • Can read and write
  • Being able to use the a mobile app through education or having someone help a participant use the mobile app
  • Having a reliable informant who could provide investigators with the requested information.
  • written informed consent
Exclusion Criteria
  • Major psychiatric illness such as major depressive disorders
  • Dementia
  • Other neurodegenerative disease (e.g., Parkinson's disease)
  • Malignancy within five years
  • Cardiac stent or revascularization within one year
  • Serious or unstable symptomatic cardiovascular disease
  • Other serious or unstable medical disease such as acute or severe asthma, active gastric ulcer, severe liver disease, or severe renal disease
  • Severe loss of vision, hearing, or communicative disability
  • Significant laboratory abnormality that may result in cognitive impairment
  • Any conditions preventing cooperation as judged by the study physician
  • Unable to participate in exercise program safely
  • Coincident participation in any other intervention trial

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
retention rateFrom enrollment to the end of intervention at 16 weeks

retention rate ≥ 70%

Adherence to the protocolFrom enrollment to the end of intervention at 16 weeks

Adherence to the protocol ≥ 70%

recruitment rateFrom enrollment to the end of intervention at 16 weeks

recruitment rate) ≥ 50%.

Secondary Outcome Measures
NameTimeMethod
Change from Baseline in Modified Fried frailty phenotype score at 16 weeksFrom baseline to the end of intervention at 16 weeks

The score ranges from 0 to 5. A lower score indicates better performance.

Change from Baseline in Korean Frailty Index for Primary Care at 16 weeksFrom baseline to the end of intervention at 16 weeks

The score ranges from 0 to 1. A lower score indicates better performance.

Change from Baseline in Lubben Social Network Scale at 16 weeksFrom baseline to the end of intervention at 16 weeks

The score ranges from 0 to 50. A higher score indicates better performance.

Change from Baseline in 14-item cognitive subscale of the Alzheimer's Disease Assessment Scale at 16 weeksFrom baseline to the end of intervention at 16 weeks

The score ranges from 0 to 90. A lower score indicates better performance.

Change from Baseline in Korean Mini-Mental State Examination-2 at 16 weeksFrom enrollment to the end of intervention at 16 weeks

The score ranges from 0 to 30. A higher score indicates better performance.

Change from Baseline in Clinical Dementia Rating scale-Sum of Boxes at 16 weeksFrom baseline to the end of intervention at 16 weeks

The score ranges from 0 to 18. A lower score indicates better performance.

Change from Baseline in Korean Instrumental Activities of Daily Living at 16 weeksFrom baseline to the end of intervention at 16 weeks

The score ranges from 0 to 3. A lower score indicates better performance.

Change from Baseline in Modified Barthel Index: at 16 weeksFrom baseline to the end of intervention at 16 weeks

The score ranges from 0 to 100. A higher score indicates better performance.

Change from Baseline in Center for Epidemiological Studies-Depression Scale at 16 weeksFrom baseline to the end of intervention at 16 weeks

The score ranges from 0 to 60. A lower score indicates better performance.

Change from Baseline in Quality of life-Alzheimer's disease at 16 weeksFrom baseline to the end of intervention at 16 weeks

The score ranges from 0 to 52. A higher score indicates better performance.

Change from Baseline in gait speed at 16 weeksFrom baseline to the end of intervention at 16 weeks

A lower score indicates better performance.

Change from Baseline in Short Physical Performance Battery at 16 weeksFrom baseline to the end of intervention at 16 weeks

The score ranges from 0 to 12. A higher score indicates better performance.

Change from Baseline inTimed Up and Go test at 16 weeksFrom baseline to the end of intervention at 16 weeks

A lower score indicates better performance.

Change from Baseline in 30 s sit-to-stand at 16 weeksFrom baseline to the end of intervention at 16 weeks

A higher score indicates better performance.

Change from Baseline in 2 min stepping test at 16 weeksFrom baseline to the end of intervention at 16 weeks

A higher score indicates better performance.

Change from Baseline in Mini Nutritional Assessment at 16 weeksFrom baseline to the end of intervention at 16 weeks

The score ranges from 0 to 14. A higher score indicates better performance.

Change from Baseline in Nutritional Quotient for Elderly at 16 weeksFrom baseline to the end of intervention at 16 weeks

The score ranges from 0 to 100. A higher score indicates better performance.

Change from Baseline in skeletal muscle mass at 16 weeksFrom baseline to the end of intervention at 16 weeks

A higher score indicates better performance.

Number of Participants with Treatment-Related Adverse EventsFrom enrollment to the end of intervention at 16 weeks

A lower score indicates better performance.

Trial Locations

Locations (3)

Inha University Hospital

🇰🇷

Incheon, Korea, Republic of

Ewha Womans University Seoul hospital

🇰🇷

Seoul, Korea, Republic of

Ajou University Hospital

🇰🇷

Suwon, Korea, Republic of

Inha University Hospital
🇰🇷Incheon, Korea, Republic of
Seong Hye Choi, MD PhD
Contact
82-32-8903659
seonghye@inha.ac.kr
Seong Hye Choi, MD, PhD
Principal Investigator

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.